Shanghai Jiaolian Drug Research and Development Co., Ltd

Quick facts

Phase 2 pipeline

• B007 · Oncology
  B007 is a small molecule that targets the PI3K/AKT signaling pathway.
• B013

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai Jiaolian Drug Research and Development Co., Ltd portfolio CI brief
• Shanghai Jiaolian Drug Research and Development Co., Ltd pipeline updates RSS

Related

• Sector hub: All tracked pharma companies